#1 Clinical Trials Search in Europe

Landiolol Hydrochloride

Landiolol Hydrochloride, an ultra-short-acting beta-blocker, is being studied in various clinical trials for its potential benefits in critical care settings. These trials aim to evaluate its effectiveness in managing conditions such as septic shock, cardiac surgery complications, and cardiac arrest. The research focuses on how Landiolol can help control heart rate, improve cardiac function, and potentially reduce mortality in critically ill patients.

Table of Contents

What is Landiolol Hydrochloride?

Landiolol Hydrochloride is a medication that belongs to a class of drugs called beta-blockers. It is an ultra-short-acting beta-blocker, which means it works quickly but its effects don’t last long in the body[1]. This medication is primarily used in hospital settings for specific heart-related conditions.

Medical Conditions Treated

Landiolol Hydrochloride is being studied and used to treat several medical conditions, including:

  • Septic shock: A severe condition that occurs when an infection leads to dangerously low blood pressure[1]
  • Cardiac surgery complications: Specifically for patients undergoing mitral valve surgery[2]
  • Cardiac arrest: When the heart suddenly stops beating[3]
  • Tachycardia: An abnormally fast heart rate[1]

How Landiolol Works

Landiolol Hydrochloride works by blocking the effects of certain natural chemicals in your body (such as epinephrine) on the heart. This helps to slow down the heart rate and reduce the workload on the heart[1]. In conditions like septic shock or after cardiac surgery, this can be beneficial in managing the body’s stress response and improving outcomes.

Administration and Dosage

Landiolol Hydrochloride is typically administered in a hospital setting through an intravenous (IV) infusion. The dosage can vary depending on the specific condition being treated and the patient’s response. For example:

  • In septic shock patients, doses ranging from 0.5 to 10 micrograms per kilogram per minute have been studied[1]
  • For cardiac surgery patients, doses up to 0.3 milligrams per kilogram have been used[2]
  • In cardiac arrest situations, up to 40 milligrams may be administered[3]

The exact dosage will be determined by your healthcare provider based on your individual needs and condition.

Current Clinical Studies

Several clinical trials are currently underway to further investigate the effectiveness of Landiolol Hydrochloride in various conditions:

  • MILANOS study: Investigating the effects of Landiolol on microcirculation in patients with septic shock[1]
  • LUNA trial: Studying the use of Landiolol in patients undergoing mitral valve surgery to prevent low cardiac output syndrome[2]
  • A study comparing Landiolol to standard care for preventing mortality in patients with septic shock and high heart rate[3]
  • A pilot trial examining the use of Landiolol in out-of-hospital cardiac arrest situations[4]

Potential Benefits

Based on ongoing research, Landiolol Hydrochloride may offer several potential benefits:

  • Improved heart function and blood flow in septic shock patients[1]
  • Reduced risk of complications after heart valve surgery[2]
  • Decreased mortality in patients with septic shock and high heart rate[3]
  • Faster recovery of normal heart rhythm in cardiac arrest situations[4]

Possible Side Effects and Precautions

While Landiolol Hydrochloride is generally well-tolerated, it may cause side effects in some patients. Potential side effects and precautions include:

  • Low blood pressure
  • Slow heart rate (bradycardia)
  • Worsening of heart failure symptoms in some cases

Landiolol should not be used in patients with certain conditions, including:

  • Severe bradycardia (very slow heart rate)
  • Cardiogenic shock
  • Severe heart block
  • Severe, untreated heart failure
  • Allergic reactions to Landiolol or its components

It’s important to note that Landiolol Hydrochloride is typically administered under close medical supervision in a hospital setting, where healthcare providers can monitor for and manage any potential side effects[1][2][3][4].

Trial Name Condition Primary Objective Key Endpoints
MILANOS Septic shock with microcirculatory abnormalities Study efficacy of Landiolol on microcirculatory vascular reactivity Variation in microcirculatory vascular reactivity, cardiac output, clinical perfusion parameters
LUNA Mitral valve surgery patients at risk of LCOS Assess Landiolol’s effect on reducing postoperative low cardiac output syndrome Occurrence of postoperative low cardiac output syndrome, catecholamine infusion duration, cardiac biomarkers
Septic Shock with Hypercontractility Septic shock with high heart rate Demonstrate improved mortality with Landiolol in septic shock patients with tachycardia and hypercontractility Mortality at day 28, heart rate reduction, shock duration, organ failure
Beta-blockade in Cardiac Arrest Out-of-hospital cardiac arrest Evaluate if Landiolol decreases time to sustained return of spontaneous circulation Time to sustained ROSC, survival rates, neurologic outcomes

FAQ

  • What is Landiolol Hydrochloride? Landiolol Hydrochloride is an ultra-short-acting beta-blocker medication. It is used to control heart rate in various medical conditions, particularly in critical care settings.
  • What conditions are being studied with Landiolol in these clinical trials? The clinical trials are studying Landiolol's effects on septic shock with microcirculatory issues, mitral valve surgery complications, septic shock with high heart rate, and out-of-hospital cardiac arrest.
  • How is Landiolol administered in these trials? Landiolol is typically administered as an intravenous infusion. The dosage and duration vary depending on the specific trial and condition being studied.
  • What are the main goals of these Landiolol clinical trials? The main goals include assessing Landiolol's ability to reduce mortality, improve cardiac function, control heart rate, reduce the occurrence of low cardiac output syndrome, and decrease the time to return of spontaneous circulation in cardiac arrest patients.
  • Are there any common side effects or risks associated with Landiolol use in these trials? While specific side effects are not detailed in the trial summaries, common concerns with beta-blockers include the risk of bradycardia (slow heart rate) and hypotension (low blood pressure). Patients with certain pre-existing conditions are typically excluded from the trials to minimize risks.

Ongoing Clinical Trials on Landiolol Hydrochloride

  • Study on Preventing Atrial Fibrillation After Heart Surgery Using Landiolol Hydrochloride in Patients with Normal Heart Function

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Austria

  • Study on the Effect of Landiolol Hydrochloride and Sodium Chloride in Patients Experiencing Cardiac Arrest

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Austria

  • Study on the Effects of Landiolol Hydrochloride for Patients with Microcirculatory Issues During Septic Shock

    Recruiting

    3 1 1 1
    Investigated drugs:
    France

  • Study on the Use of Landiolol Hydrochloride and Sodium Chloride for Patients Undergoing Mitral Valve Surgery to Prevent Low-Cardiac Output Syndrome

    Recruiting

    3 1 1
    Investigated drugs:
    Italy

  • A study testing landiolol in patients with ST-elevation acute coronary syndrome undergoing primary percutaneous coronary intervention

    Not yet recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Austria

  • Study on Landiolol Hydrochloride and Sodium Chloride for Reducing Mortality in Patients with Septic Shock and High Heart Rate

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Landiolol Hydrochloride: An ultra-short-acting beta-blocker medication used to control heart rate in various medical conditions, particularly in critical care settings.
  • Septic shock: A life-threatening condition that occurs when sepsis leads to dangerously low blood pressure and abnormalities in cellular metabolism.
  • Microcirculatory abnormalities: Problems in the smallest blood vessels of the body, which can affect blood flow and oxygen delivery to tissues.
  • Low cardiac output syndrome (LCOS): A condition where the heart is unable to pump enough blood to meet the body's needs, often occurring after heart surgery.
  • Mitral valve surgery: A surgical procedure to repair or replace the mitral valve in the heart.
  • Cardioplegia: A technique used in heart surgery to temporarily stop the heart by using a special solution.
  • Tachycardia: An abnormally rapid heart rate, typically over 100 beats per minute in adults.
  • Hypercontractility: An increased force of contraction of the heart muscle.
  • Cardiac arrest: A sudden loss of heart function, breathing, and consciousness.
  • Return of Spontaneous Circulation (ROSC): The resumption of sustained heart activity and blood circulation after cardiac arrest.
  • Ventricular fibrillation (VF): A type of irregular heart rhythm where the ventricles of the heart quiver instead of pumping blood effectively.
  • Beta-blocker: A class of medications that block the effects of adrenaline and noradrenaline on the heart, typically used to slow heart rate and reduce blood pressure.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effects-of-landiolol-hydrochloride-for-patients-with-microcirculatory-issues-during-septic-shock/
  2. http://clinicaltrials.eu/trial/study-on-the-use-of-landiolol-hydrochloride-and-sodium-chloride-for-patients-undergoing-mitral-valve-surgery-to-prevent-low-cardiac-output-syndrome/
  3. http://clinicaltrials.eu/trial/study-on-landiolol-hydrochloride-and-sodium-chloride-for-reducing-mortality-in-patients-with-septic-shock-and-high-heart-rate/
  4. http://clinicaltrials.eu/trial/study-on-the-effect-of-landiolol-hydrochloride-and-sodium-chloride-in-patients-experiencing-cardiac-arrest/